ClinicalTrials.gg
Enrolling by invitationNCT07770347Updated Nov 18, 2026

Immunity in Critical Sepsis

An interventional study of Individualized anti-infective therapy and Individualized immunomodulatory therapy in Sepsis, sponsored by Beijing Chao Yang Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Chao Yang Hospital · Not applicable, Interventional, and Other

Updated Nov 18, 2026Interventions changedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 285 studies in Sepsis with a site in China — 98 open to participants now, 105 under way, 5 of them phase 3. Sepsis · China.

Planned enrollment
3rd of 120
2,400 · median 119
Started
2026
with 31 others
No phase
66 of 285
27 open now
Primary completion
2031-06
later than 103 of 104 live
Registered
271st of 285
by date

Among the 285 studies in Sepsis with a site in China, this one is the 3rd largest by planned enrollment of the 120 interventional ones that give a count, is one of 32 that started in 2026, is one of 66 with no phase, reaches primary completion later than 103 of the 104 other live ones, and was the 271st registered.

Sepsis

2,421 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

98 of the 285 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 321 Sepsis studies recruiting now, 213 (66%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 285 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection, and remains the leading cause of death in critical care medicine worldwide. According to the 2024 Global Burden of Disease data, there are 48.9 million new cases and 11 million deaths annually worldwide, with 11 million deaths accounting for 19.7% of all global deaths. In China, the incidence of sepsis continues to rise due to population aging, increased invasive procedures, overuse of antimicrobials, the prevalence of multidrug-resistant organisms, and a growing number of patients with chronic diseases. Regional studies indicate that the incidence of sepsis in Chinese ICUs ranges from 15% to 30%, with mortality rates as high as 40% to 60%-far exceeding those in developed countries. Among critically ill patients admitted to the ICU-such as those with severe trauma, major surgery, acute respiratory distress syndrome, severe pancreatitis, and advanced malignancies-hospital-acquired infections leading to secondary sepsis represent the most critical trigger for clinical deterioration, multiple organ dysfunction syndrome (MODS), and death. This creates a vicious cascade of "primary disease exacerbation → nosocomial infection → sepsis → MODS → death", resulting in skyrocketing costs, prolonged hospital stays, and heavy burdens on families and society.To address this challenge, this project aims to: (1) establish the largest and internationally leading multimodal dataset for severe sepsis in China, covering 19 tertiary ICUs nationwide over a 5-year period, with 5,300 critically ill patients including 800 sepsis cases, integrating clinical data, immunological indicators, biomarkers, microbiological data, imaging, longitudinal biospecimens, and long-term follow-up information into a standardized, shareable, and sustainable national sepsis database; (2) systematically elucidate the three core pathophysiological mechanisms of severe sepsis-identifying risk factors, pathogen profiles, antimicrobial resistance patterns, and early warning indicators; revealing the dynamic dysregulation patterns of cellular immunity, humoral immunity, and innate immunity to establish immunophenotyping standards; and clarifying the risk factors, mechanisms, and subtype characteristics of multiple organ injury; (3) foster interdisciplinary collaboration between medical and engineering sciences to develop a series of precision diagnostic and therapeutic tools, including AI-assisted early infection warning systems, rapid immunotyping assays, multi-organ injury prediction models, and individualized prognostic calculators for real-time, accurate, and non-invasive bedside assessment; (4) establish a comprehensive precision management system for sepsis, forming an integrated "prevention-early warning-diagnosis-immunotyping-stratified treatment-prognostic evaluation-rehabilitation" care pathway; (5) drive clinical translation to improve patient outcomes, aiming to reduce ICU sepsis incidence, mortality, and healthcare costs, while improving long-term quality of life, cognitive function, and psychological status of survivors and reducing readmission rates; and (6) build a national-level sepsis research platform and cultivate talent by establishing a nationwide collaborative research network, and training professionals with integrated clinical-research-translational competencies.

03

Conditions studied

  • Sepsis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • ICU stay ≥ 24 hours
  • signed by the patient or their legal representative

Exclusion criteria

Exclusion Criteria:

  • ICU stay \< 24 hours
  • Refusal to provide
  • Pregnancy or lactation
  • Receiving palliative care or expected survival \< 24 hours
  • Previously enrolled in this study
  • Severe immunodeficiency ( infection, or long-term use of /)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
2,400 participants (estimated)

Study arms

  • No intervention
    Control group
  • Experimental
    Treatment group

    Other: Individualized anti-infective therapy · Other: Individualized immunomodulatory therapy · Other: Individualized organ function support therapy · Other: Standardized ICU nursing care strategies · Other: Individualized sedation and analgesia therapy

Interventions

  • OtherIndividualized anti-infective therapy

    Antimicrobial agents (e.g., broad-spectrum or targeted antibiotics, antifungals) selected and adjusted by the attending physician based on suspected/confirmed infection source, culture and susceptibility results, and institutional antimicrobial stewardship protocols.

  • OtherIndividualized immunomodulatory therapy

    Immunomodulatory agents (e.g., corticosteroids, intravenous immunoglobulin) administered at the discretion of the attending physician according to the patient's immune/inflammatory status and relevant clinical guidelines.

  • OtherIndividualized organ function support therapy

    Organ support measures (e.g., mechanical ventilation, continuous renal replacement therapy, vasoactive agents) initiated and titrated by the treating team based on the patient's evolving organ function status.

  • OtherStandardized ICU nursing care strategies

    Nursing care measures (e.g., protocolized sedation/analgesia management, glycemic control, pressure injury prevention, early mobilization) delivered according to unit-based standardized nursing protocols.

  • OtherIndividualized sedation and analgesia therapy

    Sedative and analgesic agents (e.g., opioids, benzodiazepines, propofol) selected and titrated by the attending physician according to the patient's sedation/analgesia requirements, clinical condition, and tolerance, to achieve the target sedation depth and pain control.

06

What researchers measure

Primary outcomes

  1. Annual incidence of sepsis in ICU

    Number of new sepsis cases (diagnosed by Sepsis-3 criteria) per 1,000 ICU admissions (or per 1,000 patient-days).

    Time frame: 90 days after enrollment.

  2. Prevalence of sepsis in ICU

    Percentage of ICU admissions meeting Sepsis-3 criteria for sepsis during the study period.

    Time frame: 90 days after enrollment

  3. Distribution of infection site (lung/abdominal/bloodstream/urinary tract)

    Percentage of patients with infection originating from the lung, abdomen, bloodstream, or urinary tract, respectively.

    Time frame: 90 days after enrollment

  4. Distribution of infection type (community-acquired/hospital-acquired/secondary)

    Percentage of patients with community-acquired, hospital-acquired, or secondary infection, respectively.

    Time frame: 90 days after enrollment

  5. Pathogen distribution (Gram-negative/Gram-positive/fungal)

    Percentage of microbiological isolates classified as Gram-negative bacteria, Gram-positive bacteria, or fungi.

    Time frame: 90 days after enrollment

  6. Antimicrobial resistance rate (CRE/CRAB/MRSA)

    Percentage of isolates identified as carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), or methicillin-resistant Staphylococcus aureus (MRSA).

    Time frame: 90 days after enrollment

  7. ICU length of stay

    Number of days from ICU admission to ICU discharge.

    Time frame: Through ICU discharge, up to 90 days

  8. Duration of mechanical ventilation

    Number of days on invasive mechanical ventilation.

    Time frame: Through 90 days

  9. Duration of vasoactive agent use

    Number of days on any vasoactive agent (e.g., norepinephrine, vasopressin, dobutamine, epinephrine).

    Time frame: Through 90 days

  10. Duration of renal replacement therapy

    Number of days receiving renal replacement therapy (continuous or intermittent).

    Time frame: Through 90 days

  11. Daily ICU cost

    Average direct cost of ICU care per patient per day, in Chinese Yuan (CNY).

    Time frame: Through ICU discharge, up to 90 days

  12. Total hospitalization cost

    Total direct cost of hospital care per patient, in Chinese Yuan (CNY), from hospital admission to discharge.

    Time frame: Through hospital discharge, up to 90 days

  13. ICU mortality

    Percentage of patients who die prior to ICU discharge.

    Time frame: Through ICU discharge, an average of 28 days

  14. In-hospital mortality

    Percentage of patients who die prior to hospital discharge.

    Time frame: Through hospital discharge, up to 90 days

  15. 28-day all-cause mortality

    Percentage of patients who die from any cause within 28 days of enrollment.

    Time frame: 28 days after enrollment

  16. 90-day all-cause mortality

    Percentage of patients who die from any cause within 90 days of enrollment.

    Time frame: 90 days after enrollment

  17. Discriminative Performance of the Infection Risk-Prediction Model

    Area under the receiver operating characteristic curve (AUC/C-statistic) of the multivariable model predicting infection occurrence, developed from patient, disease, and treatment-related candidate predictors using Cox regression, LASSO, and propensity score analysis.

    Time frame: 90 days after enrollment

  18. Sensitivity and Specificity of the Infection Risk-Prediction Score

    Sensitivity and specificity (%) of the infection risk-prediction score at its optimal cutoff value, determined by the Youden index.

    Time frame: 90 days after enrollment

  19. Hand Hygiene Compliance Rate

    Percentage of observed hand hygiene opportunities performed correctly, per WHO Five Moments guidance.

    Time frame: 90 days after enrollment

  20. Catheter Care Bundle Compliance Rate

    Percentage of eligible patient-days with full compliance to central line and urinary catheter care bundle elements.

    Time frame: 90 days after enrollment

  21. Diagnostic Accuracy of Procalcitonin (PCT)

    Area under the receiver operating characteristic curve (AUC) of serum Procalcitonin (PCT) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  22. Diagnostic Accuracy of C-Reactive Protein (CRP)

    Area under the receiver operating characteristic curve (AUC) of serum C-Reactive Protein (CRP) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  23. Diagnostic Accuracy of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1)

    Area under the receiver operating characteristic curve (AUC) of serum Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  24. Diagnostic Accuracy of Presepsin

    Area under the receiver operating characteristic curve (AUC) of serum Presepsin concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  25. Diagnostic Accuracy of Soluble Urokinase Plasminogen Activator Receptor (suPAR)

    Area under the receiver operating characteristic curve (AUC) of serum Soluble Urokinase Plasminogen Activator Receptor (suPAR) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  26. Diagnostic Accuracy of Interleukin-6 (IL-6)

    Area under the receiver operating characteristic curve (AUC) of serum Interleukin-6 (IL-6) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  27. Diagnostic Accuracy of Interleukin-8 (IL-8)

    Area under the receiver operating characteristic curve (AUC) of serum Interleukin-8 (IL-8) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  28. Diagnostic Accuracy of Pro-Adrenomedullin (Pro-ADM)

    Area under the receiver operating characteristic curve (AUC) of serum Pro-Adrenomedullin (Pro-ADM) concentration for differentiating infection from non-infection and sepsis from non-sepsis, with corresponding sensitivity, specificity, and optimal cutoff value.

    Time frame: At enrollment (baseline), and at 72 hours after enrollment

  29. AUC of Combined Multi-Parameter Early-Warning Model

    Area under the receiver operating characteristic curve of a composite model integrating vital signs (temperature, heart rate, respiratory rate, blood pressure, SpO2), laboratory values, and the biomarkers listed above for early warning of infection.

    Time frame: From 24 hours before to 72 hours after infection onset

  30. Diagnostic Accuracy of AI-Based Automated Warning System

    Accuracy (%) of a machine-learning-based (random forest, XGBoost, deep learning) automated warning system using electronic medical record data to predict infection onset.

    Time frame: From 24 hours before to 72 hours after infection onset

  31. Lead Time of AI-Based Warning System

    Time interval, in hours, between the AI system alert and the subsequent clinical diagnosis of infection.

    Time frame: Up to 24 hours before clinical diagnosis

  32. Time to First Effective Antibiotic Administration

    Time, in hours, from infection recognition to administration of the first in vitro active antibiotic.

    Time frame: Within 6 hours of infection onset

  33. Rate of Appropriate Empirical Antibiotic Therapy

    Percentage of patients receiving empirical antibiotic therapy subsequently confirmed to be active against the identified pathogen(s).

    Time frame: 90 days after enrollment

  34. Rate of Antibiotic Coverage of Resistant Organisms

    Percentage of patients with identified multidrug-resistant organisms whose empirical antibiotic regimen provided adequate in vitro coverage.

    Time frame: 90 days after enrollment

  35. Antibiotic De-escalation Rate

    Percentage of patients whose antibiotic regimen was narrowed (de-escalated) based on culture and susceptibility results.

    Time frame: 90 days after enrollment

  36. Duration of Antibiotic Therapy

    Number of days of antibiotic treatment administered for the index infection.

    Time frame: 90 days after enrollment

  37. Time to Source Control

    Time, in hours, from infection recognition to definitive source-control intervention (drainage, debridement, catheter removal, or surgery).

    Time frame: 90 days after enrollment

  38. Compliance Rate with SSC Bundle Elements

    Percentage of eligible patients/bundle elements for which Surviving Sepsis Campaign bundle elements were completed within the recommended time window.

    Time frame: 90 days after enrollment

  39. Total hospital length of stay

    Number of days from hospital admission to hospital discharge.

    Time frame: Through hospital discharge, up to 90 days

Secondary outcomes

  1. CD3+ T Lymphocyte Count/Percentage

    Absolute count (cells/μL) and/or percentage of CD3+ T lymphocytes, measured by flow cytometry.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  2. CD4+ T Lymphocyte Count/Percentage

    Absolute count (cells/μL) and/or percentage of CD4+ T lymphocytes, measured by flow cytometry.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  3. CD8+ T Lymphocyte Count/Percentage

    Absolute count (cells/μL) and/or percentage of CD8+ T lymphocytes, measured by flow cytometry.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  4. CD4+/CD8+ Ratio

    Ratio of CD4+ to CD8+ T lymphocyte counts, calculated from flow cytometry measurements

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  5. Regulatory T Cell (Treg) Percentage

    Percentage of CD4+CD25+FoxP3+ regulatory T cells among total CD4+ T cells, measured by flow cytometry.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  6. Th1/Th2 Ratio

    Ratio of Th1 to Th2 helper T cell subsets, measured by flow cytometry.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  7. Monocyte HLA-DR (mHLA-DR) Expression

    Monocyte human leukocyte antigen-DR expression, measured by flow cytometry and reported as mean fluorescence intensity or percentage of HLA-DR-positive monocytes.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  8. Natural Killer (NK) Cell Count/Percentage

    Absolute count (cells/μL) and/or percentage of NK cells, measured by flow cytometry.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  9. Absolute Lymphocyte Count

    Total lymphocyte count, in cells/μL, measured by complete blood count with differential.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  10. Lymphocyte Apoptosis Rate

    Percentage of lymphocytes undergoing apoptosis, measured by flow cytometry (e.g., Annexin V/propidium iodide staining).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  11. Monocyte Phagocytic Index

    Percentage of monocytes demonstrating phagocytic activity, measured by flow cytometry-based phagocytosis assay, reported as percentage of phagocytic monocytes (%).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  12. Serum Ferritin Concentration

    Serum ferritin concentration, in ng/mL, measured by immunoassay.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  13. Serum IgG Concentration

    Serum concentration of IgG, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  14. Serum IgA Concentration

    Serum concentration of IgA, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  15. Serum IgM Concentration

    Serum concentration of IgM, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  16. Complement C3 Concentration

    Serum concentration of C3, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  17. Complement C4 Concentration

    Serum concentration of C4, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  18. Complement C5a Concentration

    Serum concentration of C5a, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  19. Serum IL-1β Concentration

    Serum concentration of IL-1β, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  20. Serum IL-2 Concentration

    Serum concentration of IL-2, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  21. Serum IL-4 Concentration

    Serum concentration of IL-4, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  22. Serum IL-6 Concentration

    Serum concentration of IL-6, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  23. Serum IL-8 Concentration

    Serum concentration of IL-8, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  24. Serum IL-10 Concentration

    Serum concentration of IL-10, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  25. Serum TNF-α Concentration

    Serum concentration of TNF-α, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  26. Serum IFN-γ Concentration

    Serum concentration of IFN-γ, measured by immunoassay (e.g., ELISA or multiplex bead-based assay).

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  27. Pro-/Anti-Inflammatory Cytokine Ratio

    Ratio of serum IL-6 to IL-10 concentration, calculated as a composite index of pro- versus anti-inflammatory balance.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  28. Incidence of Immunoparalysis

    Percentage of patients with monocyte HLA-DR (mHLA-DR) expression below 8,000 antibodies/cell (measured by quantitative flow cytometry, QuantiBRITE method), indicating immunoparalysis.

    Time frame: Through 5 days after enrollment

  29. Duration of Immunoparalysis

    Number of days during which mHLA-DR expression remains below the pre-specified immunoparalysis threshold.

    Time frame: Through day 5 after enrollment

  30. Time to Onset of Immunoparalysis

    Time, in hours, from infection recognition to the first mHLA-DR measurement below the pre-specified immunoparalysis threshold.

    Time frame: Within 24 hours after infection onset

  31. Proportion of Patients with Hyperinflammatory Immune Phenotype

    Percentage of patients classified as hyperinflammatory phenotype (high IL-6/TNF-α/ferritin, low IL-10, normal CD4+/mHLA-DR) by unsupervised clustering (K-means/latent class analysis/PCA) of the immune parameters listed above.

    Time frame: Within 5 days after enrollment

  32. Proportion of Patients with Immunosuppressive Immune Phenotype

    Percentage of patients classified as immunosuppressive phenotype (normal IL-6/TNF-α/ferritin, high IL-10, low CD4+, high Treg, low mHLA-DR) by the same clustering method.

    Time frame: Within 5 days after enrollment

  33. Proportion of Patients with Mixed Immune Phenotype

    Percentage of patients classified as mixed phenotype (concurrently elevated pro- and anti-inflammatory markers) by the same clustering method.

    Time frame: Within 5 days after enrollment

  34. Sensitivity and Specificity of Bedside Rapid Immunophenotyping Test

    Sensitivity and specificity (%) of a bedside rapid test/scoring tool for immune phenotype classification, benchmarked against the reference clustering-based classification.

    Time frame: Within 5 days after enrollment

  35. Time to Complete Bedside Immunophenotyping Test

    Time, in minutes, required to obtain a result from the bedside rapid immunophenotyping test.

    Time frame: Within 5 days after enrollment

  36. Plasma Angiopoietin-2 (Ang-2) Concentration

    Plasma Ang-2 concentration, in pg/mL, measured by immunoassay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  37. Soluble VCAM-1 Concentration

    Serum/plasma soluble vascular cell adhesion molecule-1 concentration, in ng/mL, measured by immunoassay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  38. VEGF Concentration

    Vascular endothelial growth factor concentration, in pg/mL, measured by immunoassay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  39. Endothelin-1 Concentration

    Plasma endothelin-1 concentration, in pg/mL, measured by immunoassay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  40. DPP3 Concentration

    Plasma dipeptidyl peptidase 3 concentration, in ng/mL, measured by immunoassay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  41. Fibrinogen Concentration

    Plasma fibrinogen concentration, in g/L, measured by standard coagulation assay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  42. Platelet Count

    Platelet count, in ×10⁹/L, measured by complete blood count.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  43. Thrombin Time

    Thrombin time, in seconds, measured by standard coagulation assay.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  44. Concentration of D-dimer

    Plasma D-dimer concentration measured at each specified timepoint, reported in μg/mL (or ng/mL FEU).

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  45. Discriminative Performance of Multi-Organ Injury Risk-Prediction Model

    Area under the receiver operating characteristic curve (AUC/C-statistic) of the multivariable model predicting multi-organ injury, developed from infection, immune, endothelial, coagulation, and patient/treatment-related candidate predictors using Cox regression, LASSO, and machine learning methods.

    Time frame: 90 days after enrollment

  46. Sensitivity and Specificity of Multi-Organ Injury Risk Score

    Sensitivity and specificity (%) of the multi-organ injury risk score at its optimal cutoff value.

    Time frame: 90 days after enrollment

  47. Composite Multi-Organ Dysfunction Score (MODS-score)

    Multi-organ dysfunction assessed by the Marshall Multiple Organ Dysfunction Score (MODS), which evaluates six organ systems (respiratory, renal, hepatic, cardiovascular, hematologic, and neurologic), each scored 0-4, for a total score ranging from 0 (no dysfunction) to 24 (maximum dysfunction). Higher scores indicate more severe multi-organ dysfunction.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, at 5 days after diagnosis and 90 days after diagnosis

  48. Serum Creatinine Concentration

    Serum creatinine concentration, in μmol/L (or mg/dL), measured by standard laboratory assay, reflecting renal function.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  49. Serum Total Bilirubin Concentration

    Serum total bilirubin concentration, in μmol/L (or mg/dL), measured by standard laboratory assay, reflecting hepatic function.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  50. Serum Troponin Concentration

    Serum concentration of high-sensitivity cardiac troponin T (hs-cTnT) or troponin I (hs-cTnI), measured by standard immunoassay, reported in ng/L (or ng/mL), reflecting myocardial injury.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  51. Serum Lactate Concentration

    Serum lactate concentration, in mmol/L, measured by standard laboratory assay.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  52. Serum Syndecan-1 Concentration

    Serum syndecan-1 concentration, in ng/mL, measured by immunoassay, reflecting glycocalyx/endothelial injury.

    Time frame: At ICU admission (baseline), at the time of infection diagnosis, at 72 hours after diagnosis, and at 5 days after diagnosis

  53. Proportion of Patients per Organ-Injury Subtype

    Percentage of patients classified as lung-predominant, kidney-predominant, heart-predominant, coagulation-predominant, or mixed subtype, based on the pattern, mechanism, and severity of organ injury.

    Time frame: Within 5 days after enrollment

  54. Rate of Multi-Organ Injury Progression

    Percentage of patients demonstrating worsening of organ-specific SOFA sub-score between baseline and 72 hours.

    Time frame: From baseline (at infection diagnosis) to 72 hours after diagnosis

  55. Rate of Multi-Organ Injury Reversibility

    Percentage of patients demonstrating recovery of organ-specific SOFA sub-score between 72 hours and day 5.

    Time frame: From 72 hours after diagnosis to 5 days after diagnosis

  56. Compliance Rate with Lung-Protective Ventilation Strategy

    Percentage of mechanically ventilated patients receiving tidal volume ≤8 mL/kg predicted body weight.

    Time frame: 90 days after enrollment

  57. Time from AKI Diagnosis to RRT Initiation

    Time, in hours, from acute kidney injury diagnosis to initiation of renal replacement therapy.

    Time frame: 90 days after enrollment

  58. Lactate Clearance Rate

    Percentage change in serum lactate concentration from baseline to 72 hours after diagnosis, calculated as (baseline lactate - 72-hour lactate) / baseline lactate × 100%.

    Time frame: From baseline (at infection diagnosis) to 72 hours after diagnosis

  59. Discriminative Performance of Prognostic Model for 28-Day Mortality

    Area under the receiver operating characteristic curve (AUC/C-statistic) of a prognostic model integrating infection, immune, and organ-injury indicators to predict 28-day all-cause mortality.

    Time frame: 28 days after enrollment

  60. Discriminative Performance of Prognostic Model for 90-Day Mortality

    Area under the receiver operating characteristic curve (AUC/C-statistic) of the same prognostic model to predict 90-day all-cause mortality.

    Time frame: 90 days after enrollment

  61. 1-Year All-Cause Survival Rate

    Percentage of enrolled patients alive at 1 year after enrollment.

    Time frame: 1 year after enrollment

  62. Hospital Readmission Rate

    Percentage of patients readmitted to the hospital for any cause within 1 year after enrollment.

    Time frame: 1 year after enrollment

  63. Cognitive Function (MoCA)

    Cognitive function assessed by the Montreal Cognitive Assessment (MoCA), scored 0-30 (higher scores indicate better cognitive function).

    Time frame: 1 year after enrollment

  64. Cognitive Function (TICS)

    Cognitive function assessed by the Telephone Interview for Cognitive Status (TICS), scored 0-41, with higher scores indicating better cognitive function.

    Time frame: 1 year after enrollment

  65. Anxiety Symptoms (HADS-Anxiety subscale)

    Anxiety symptoms assessed by the Hospital Anxiety and Depression Scale, Anxiety subscale (HADS-A), scored 0-21 (higher scores indicate more severe anxiety).

    Time frame: 1 year after enrollment

  66. Depressive Symptoms (HADS-Depression subscale)

    Depressive symptoms assessed by the Hospital Anxiety and Depression Scale, Depression subscale (HADS-D), scored 0-21 (higher scores indicate more severe depression).

    Time frame: 1 year after enrollment

  67. Post-Traumatic Stress Symptoms

    Post-traumatic stress symptoms assessed by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure scored 0-80, with higher scores indicating more severe post-traumatic stress symptoms.

    Time frame: 1 year after enrollment

  68. Functional Disability (mRS)

    Functional disability assessed by the modified Rankin Scale (mRS), scored 0-6 (higher scores indicate greater disability).

    Time frame: 1 year after enrollment

  69. Activities of Daily Living (Barthel Index)

    Activities of daily living assessed by the Barthel Index, scored 0-100 (higher scores indicate greater independence).

    Time frame: 1 year after enrollment

  70. Muscle Function

    Muscle function assessed by the Medical Research Council (MRC) sum score, which evaluates strength in six muscle groups bilaterally (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors), each scored 0-5, for a total score ranging from 0 (complete paralysis) to 60 (normal strength). Lower scores indicate greater muscle weakness; an MRC sum score \<48 is commonly used to define ICU-acquired weakness.

    Time frame: 1 year after enrollment

  71. Health-Related Quality of Life (EQ-5D-5L Utility Index)

    Health-related quality of life assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) descriptive system, reported as a utility index value derived using the Chinese value set. The utility index ranges from -0.391 (worst health state) to 1.0 (full health), with higher scores indicating better health-related quality of life. A score of 0 represents a health state equivalent to death, and negative scores represent health states considered worse than death.

    Time frame: 1 year after enrollment

  72. Health-Related Quality of Life (EQ-VAS)

    Health-related quality of life assessed by the EQ-5D-5L Visual Analogue Scale, scored 0-100 (higher scores indicate better self-rated health).

    Time frame: 1 year after enrollment

  73. Concentration of Plasmin-Antiplasmin Complex (PAP)

    Plasma PAP complex concentration measured at each specified timepoint, reported in ng/mL.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  74. Concentration of Tissue Plasminogen Activator (tPA)

    Plasma tPA concentration measured at each specified timepoint, reported in ng/mL

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  75. Concentration of Plasminogen Activator Inhibitor-1 (PAI-1)

    Plasma PAI-1 concentration measured at each specified timepoint, reported in ng/mL

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  76. Concentration of Fibrin/Fibrinogen Degradation Products (FDP)

    Plasma FDP concentration measured at each specified timepoint, reported in μg/mL.

    Time frame: At ICU admission (baseline), at the time of sepsis diagnosis, and at 72 hours after sepsis diagnosis

  77. Sedation Success Rate

    Proportion of patients achieving the preset sedation target (RASS score within the target range) without protocol-defined sedation failure events (e.g., requiring sedative switch, rescue sedation, or severe sedation-related adverse events).

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  78. Rate of Achieving Target RASS

    Proportion of total RASS assessments in which the actual RASS score falls within the target range preset by the attending physician.

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  79. Incidence of Rescue Sedation

    Proportion of patients receiving protocol-defined rescue sedative agents (e.g., additional bolus sedation) due to inadequate sedation.

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  80. Number of Sedative Dose Adjustments

    Total number of infusion rate or dose adjustments of sedative agents per patient.

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  81. Rate of Sedative Switch

    Proportion of patients who switch the primary sedative agent due to inadequate efficacy or adverse effects.

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  82. Proportion of Combination Sedation

    Proportion of patients receiving ≥2 sedative agents concurrently (e.g., benzodiazepine combined with propofol or dexmedetomidine).

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  83. Cumulative Sedative Dose

    Cumulative dose of each sedative agent administered during the study period (recorded separately by drug, converted to standard units such as mg or μg/kg/min·h).

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  84. Time from Sedation Cessation to Awakening

    Time interval from cessation of sedative infusion to the patient meeting awakening criteria (e.g., able to follow simple commands; RASS 0 to -1 or S5).

    Time frame: From sedation cessation until ICU discharge or day 28, whichever occurs first.

  85. Days Alive Without Delirium and Coma at 7 Days

    Number of days within 7 days after enrollment during which the patient is alive and free of both delirium (CAM-ICU negative) and coma (RASS ≥ -3 or able to complete CAM-ICU assessment).

    Time frame: Within 7 days after study enrollment.

  86. Coma-Free Days at 7 Days

    Number of days within 7 days after enrollment during which the patient is non-comatose (RASS ≥ -3).

    Time frame: Within 7 days after study enrollment.

  87. Duration of Delirium

    Number of days from the first positive CAM-ICU assessment to the last positive CAM-ICU assessment (or resolution of delirium).

    Time frame: From enrollment until ICU discharge or day 28, whichever occurs first.

  88. Incidence of New-Onset Delirium

    Proportion of patients without delirium at enrollment who develop at least one positive CAM-ICU assessment (when non-comatose and evaluable) during the study period.

    Time frame: Within 7 days after study enrollment.

  89. Time to Awakening

    Time interval from enrollment (or sedation cessation) to the first time the patient meets awakening criteria.

    Time frame: From enrollment until ICU discharge or day 28, whichever occurs first.

  90. Ventilator-Free Days at 28 Days

    Number of days within 28 days after enrollment during which the patient is alive and free of invasive mechanical ventilation; patients who die within 28 days are assigned 0 days.

    Time frame: Within 28 days after study enrollment.

  91. Successful Extubation Rate

    Proportion of patients extubated without re-intubation or rescue non-invasive ventilation within 48 hours after extubation.

    Time frame: From enrollment until ICU discharge or day 28, whichever occurs first.

  92. Re-intubation Rate

    Proportion of patients requiring re-intubation within 48 hours after planned extubation.

    Time frame: Within 48 hours after extubation.

  93. Incidence of Hypotension

    Proportion of patients with protocol-defined hypotensive events (e.g., systolic blood pressure \<90 mmHg or \>30% decrease from baseline, or hypotension requiring intervention).

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  94. Incidence of Bradycardia

    Proportion of patients with protocol-defined bradycardia (e.g., heart rate \<50 beats/min or bradycardia requiring intervention).

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  95. Rate of Vasoactive Agent Use

    Proportion of patients receiving any vasoactive agent (vasopressor or inotrope) during the study period.

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  96. Changes in Vasoactive Agent Dose

    Number of dose adjustments or magnitude of dose change of vasoactive agents (e.g., change in norepinephrine-equivalent dose).

    Time frame: Within 72 hours after initiation of the study sedation strategy.

  97. Unplanned Extubation

    Proportion of patients with unplanned (self- or accidental) removal of the endotracheal tube.

    Time frame: From enrollment until ICU discharge or day 28, whichever occurs first.

  98. Unplanned Device Removal

    Proportion of patients with unplanned removal or dislodgement of other critical devices (e.g., central venous catheter, arterial line, gastric tube, drainage tube).

    Time frame: From enrollment until ICU discharge or day 28, whichever occurs first.

  99. Adverse Events Related to Sedative/Analgesic Agents

    Incidence of adverse events judged by the investigator to be related to sedative/analgesic agents (e.g., respiratory depression, delirium, withdrawal syndrome, allergic reactions).

    Time frame: From enrollment until ICU discharge or day 28, whichever occurs first.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2031, 60 months after the start.

Of 302 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 60 months is above that.

Counting every sponsor, half of 325 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 18, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Individualized sedation and analgesia therapy
Nov 18, 2026
Secondary outcomes
23 added
What changed in the outcomes
  • AddedSedation Success RateTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedRate of Achieving Target RASSTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedIncidence of Rescue SedationTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedNumber of Sedative Dose AdjustmentsTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedRate of Sedative SwitchTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedProportion of Combination SedationTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedCumulative Sedative DoseTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedTime from Sedation Cessation to AwakeningTime frame: From sedation cessation until ICU discharge or day 28, whichever occurs first.
  • AddedDays Alive Without Delirium and Coma at 7 DaysTime frame: Within 7 days after study enrollment.
  • AddedComa-Free Days at 7 DaysTime frame: Within 7 days after study enrollment.
  • AddedDuration of DeliriumTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
  • AddedIncidence of New-Onset DeliriumTime frame: Within 7 days after study enrollment.
  • AddedTime to AwakeningTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
  • AddedVentilator-Free Days at 28 DaysTime frame: Within 28 days after study enrollment.
  • AddedSuccessful Extubation RateTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
  • AddedRe-intubation RateTime frame: Within 48 hours after extubation.
  • AddedIncidence of HypotensionTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedIncidence of BradycardiaTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedRate of Vasoactive Agent UseTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedChanges in Vasoactive Agent DoseTime frame: Within 72 hours after initiation of the study sedation strategy.
  • AddedUnplanned ExtubationTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
  • AddedUnplanned Device RemovalTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
  • AddedAdverse Events Related to Sedative/Analgesic AgentsTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
Nov 18, 2026
Sponsor
Collaborators added: Sixth Hospital of Shanxi Medical University; collaborators removed: General Hospital of Taiyuan Iron & Steel Company
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Secondary outcomes 23 added
    What changed in the outcomes
    • AddedSedation Success RateTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedRate of Achieving Target RASSTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedIncidence of Rescue SedationTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedNumber of Sedative Dose AdjustmentsTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedRate of Sedative SwitchTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedProportion of Combination SedationTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedCumulative Sedative DoseTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedTime from Sedation Cessation to AwakeningTime frame: From sedation cessation until ICU discharge or day 28, whichever occurs first.
    • AddedDays Alive Without Delirium and Coma at 7 DaysTime frame: Within 7 days after study enrollment.
    • AddedComa-Free Days at 7 DaysTime frame: Within 7 days after study enrollment.
    • AddedDuration of DeliriumTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
    • AddedIncidence of New-Onset DeliriumTime frame: Within 7 days after study enrollment.
    • AddedTime to AwakeningTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
    • AddedVentilator-Free Days at 28 DaysTime frame: Within 28 days after study enrollment.
    • AddedSuccessful Extubation RateTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
    • AddedRe-intubation RateTime frame: Within 48 hours after extubation.
    • AddedIncidence of HypotensionTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedIncidence of BradycardiaTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedRate of Vasoactive Agent UseTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedChanges in Vasoactive Agent DoseTime frame: Within 72 hours after initiation of the study sedation strategy.
    • AddedUnplanned ExtubationTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
    • AddedUnplanned Device RemovalTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
    • AddedAdverse Events Related to Sedative/Analgesic AgentsTime frame: From enrollment until ICU discharge or day 28, whichever occurs first.
    Interventions Added Individualized sedation and analgesia therapy
    Sponsor Collaborators added: Sixth Hospital of Shanxi Medical University; collaborators removed: General Hospital of Taiyuan Iron & Steel Company

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07770347
Collaborators
The People's Hospital of Hebei Province, Tianjin First Central Hospital, Second Hospital of Shanxi Medical University, Beijing Obstetrics and Gynecology Hospital, Affiliated Hospital of Hebei University, Hebei Provincial Hospital of Traditional Chinese Medicine, Hangzhou Hospital of Traditional Chinese Medicine, Baoding First Central Hospital, Beijing Shuyi Hospital, Cangzhou Central Hospital, Hengshui People's Hospital, Sixth Hospital of Shanxi Medical University, Changzhi People's Hospital, Jincheng People's Hospital, Xinxiang Central Hospital, Luohe Central Hospital, Inner Mongolia Baogang Hospital, Tianjin Medical University Cancer Institute and Hospital
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Jun 30, 2026
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion